Stockwinners Market Radar for March 18, 2018 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:01 EDT On The Fly: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Data analytics firm Cambridge Analytica harvested private information from more than 50M Facebook (FB) users in developing techniques to support President Donald Trump's 2016 election campaign, according to The New York Times. Several U.S. Republican lawmakers have expressed concern over privacy violations after the news report. 2. CACI International (CACI) announced that it has made a proposal to acquire all outstanding shares of CSRA (CSRA) for $44.00 per share in cash and stock. CACI's proposal includes a cash component of $15 per share and a stock component in the form of CACI stock at a fixed exchange ratio of 0.184 shares of CACI common stock for each share of CSRA stock. The acquisition proposal represents an 8% premium over the price CSRA's shareholders would receive in the announced transaction with General Dynamics (GD). CACI also raised its FY18 EPS outlook to $11.26-$11.50 from $10.95-$11.19, and its FY18 revenue forecast to $4.4B-$4.5B from $4.35B-$4.5B. 3. Old Navy is enjoying fast sales growth and plump profit margins but is trapped inside Gap (GPS), a name that has been an investor turnoff, Jack Hough wrote in this week's edition of Barron's. Old Navy contributes close to half of company sales and within two years could generate three-quarters of profits, and yet Gap shares trade at just 12 times projected earnings for the next four quarters, which is one sign Gap could have plenty of upside left - perhaps 25% or more over the coming year, he added. 4. Disney (DIS) and Marvel Studios' "Black Panther" continues to make history in its fifth weekend at the domestic box office with another $27M. The superhero film, which scored 97% from Rotten Tomatoes and got an A+ CinemaScore from movie audiences, is only the seventh movie ever to cross the $600M mark in North America. 5. Allergan (AGN) saw a positive mention in Barron's.

18:50 EDT CACI announces proposal to acquire CSRA for $44 per share - CACI International (CACI) announced that it has made a proposal to acquire all outstanding shares of CSRA (CSRA) for $44.00 per share in cash and stock. CACI's proposal includes a cash component of $15 per share and a stock component in the form of CACI stock at a fixed exchange ratio of 0.184 shares of CACI common stock for each share of CSRA stock. The acquisition proposal represents an 8% premium over the price CSRA's shareholders would receive in the announced transaction with General Dynamics (GD). The combination would allow CSRA's shareholders to participate in the long-term growth of the combined company. CACI expects to realize $165M annually in net run-rate cost synergies-a substantially greater figure than the synergies contemplated by the GD transaction, affording both CACI's and CSRA's shareholders the opportunity to participate in additional value creation. CACI has committed financing in place for the proposed transaction and therefore its proposal is not subject to any financing contingency. CACI's Board of Directors unanimously approved the proposal, which is not subject to any further due diligence. CACI expects that a transaction could close by July 31, 2018, subject to approvals by CACI's and CSRA's shareholders.

14:50 EDT Strongbridge Biopharma presents new data from in vitro study of levoketoconazole - Strongbridge Biopharma announced that results from an in vitro study of levoketoconazole, the active ingredient in RECORLEV, were presented at ENDO 2018, the Annual Meeting of the Endocrine Society, taking place in Chicago, Illinois from March 17 - 20, 2018. The study aimed to characterize the potency and mechanism of 2S,4R-ketoconazole - levoketoconazole, the active ingredient of RECORLEV - inhibition of human steroidogenic enzymes in intact cells in vitro. Levoketoconazole was significantly more potent than the 2R,4S-isomer and approximately twice as potent as racemic ketoconazole for CYPs 11A1, 11B1 and 17A1; the potency differences were less marked for CYP 11B2. Ketoconazole or its enantiomers did not inhibit CYPs 19A1 or 21A2 at up to 1000 nanomolar concentration. The degree of potency differences suggests that levoketoconazole accounts for essentially all of the activity of racemic ketoconazole to inhibit cortisol biosynthesis in humans. Spectral binding constants were about three to five times higher than the IC50 for CYPs 17A1 and 11B1 in intact cells, suggesting that, for these enzymes, a second mode of inhibition not involving the canonical binding pockets of these steroidogenic enzymes accounts for a significant portion of the much greater inhibition potency of levoketoconazole as compared with its mirror-opposite isomer 2R,4S-ketoconazole. RECORLEV, or levoketoconazole, is an investigational cortisol synthesis inhibitor being evaluated in LOGICS and SONICS, two Phase 3 clinical trials for endogenous Cushing's syndrome. The safety and efficacy of RECORLEV for the treatment of endogenous Cushing's syndrome have not been established.

10:16 EDT Radius Health presents positive data for ACTIVExtend BMD Responder Analysis - Radius Health presented results from "Response Rates for Hip, Femoral Neck, and Lumbar Spine Bone Mineral Density, or BMD, in Patients Treated with Abaloparatide Followed by Alendronate - Results from Phase 3 ACTIVExtend at ENDO 2018, the Endocrine Society's 100th Annual Meeting and Expo in Chicago. In ACTIVExtend, patients who had completed 18 months of TYMLOS injection or placebo in the ACTIVE Phase 3 trial were transitioned to receive 24 additional months of open-label alendronate, a bisphosphonate. BMD was measured at the lumbar spine, total hip, and femoral neck from the beginning of ACTIVE to the end of ACTIVExtend. A responder was defined as a patient with BMD increases at all three sites. BMD response rates increased in both the abaloparatide followed by alendronate group and the placebo followed by alendronate group from ACTIVE baseline through the 43 months of ACTIVExtend. In addition, there were significantly greater BMD response rates in the abaloparatide followed by alendronate group vs. the placebo followed by alendronate group at all three sites combined for BMD increases of more than 0 percent, 3 percent, and 6 percent at 43 months and at each anatomic site for BMD increases of more than 3 percent and 6 percent at each visit and at 43 months. Abaloparatide caused a dose-dependent increase in the incidence of osteosarcoma in male and female rats. The effect was observed at systemic exposures to abaloparatide ranging from 4-28 times the exposure in humans receiving the 80 mcg dose. It is unknown if TYMLOS will cause osteosarcoma in humans.